TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)
$11.13 -0.56 (-4.7904%)
Analysed TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) News Sources
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
21-07-2026
yahoo.com
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
22-07-2026
yahoo.com
Telix H1 2026 Results: Investor Webcast Notification
30-07-2026
yahoo.com
Telix to Host R&D Day in New York City on September 22, 2026
05-08-2026
yahoo.com
Telix opens radiopharmaceutical facility in Australia for cancer treatment
16-07-2026
pharmaceutical-technology.com
How Telix landed a $2.1 billion radiopharma deal with Regeneron
30-07-2026
pharmavoice.com
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
20-08-2026
yahoo.com
Telix Pharmaceuticals H1 Earnings Call Highlights
20-08-2026
marketbeat.com
Telix Pharmaceuticals Ltd (TLPPF) (H1 2026) Earnings Call Highlights: Revenue Surges 22% to ...
20-08-2026
yahoo.com
Telix Pharmaceuticals Limited Q2 2026 Earnings Call Summary
21-08-2026
moby.co
What is the current price of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The current price of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is $11.13.
TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) absolute price change since previous trading day?
The absolute price change of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) since the previous trading day is $-0.56.
TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) percentage price change since previous trading day?
The percentage price change of TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) since the previous trading day is -4.7904%.
What is the most recent average sentiment score for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The most recent average sentiment score for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)?
The most recent sentiment for TELIX PHARMACEUTICALS LTD (TLX:NASDAQ) is .
SEC-8K** Filing Available For TELIX PHARMACEUTICALS LTD (TLX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.